Molecular Formula | C6H11NO2 |
Molar Mass | 129.16 |
Density | 1.064±0.06 g/cm3(Predicted) |
Melting Point | 209℃ |
Boling Point | 277.7±28.0 °C(Predicted) |
Solubility | Methanol (Slightly), Water (Slightly) |
Appearance | neat |
Color | Off-White |
pKa | 4.36±0.10(Predicted) |
Storage Condition | 2-8°C |
In vitro study | A significant increase in seizure threshold is observed following systemic (i.p.) administration of high (600 or 1200 mg/kg) doses of Vigabatrin. Bilateral microinjection of Vigabatrin (10 μg) into either the anterior or posterior substantia nigra pars reticulata (SNr) also increased seizure threshold, but less markedly than systemic treatment. Focal delivery into the subthalamic nucleus (STN) increased seizure threshold more markedly than either intranigral or systemic administration of Vigabatrin. |
In vivo study | Vigabatrin inhibits the uptake of taurine in Caco-2 and MDCK cells to 34% and 53%, respectively, at a concentration of 30 mM. In Caco-2 cells the uptake of Vigabatrin under neutral pH conditions is concentration-dependent and saturable with a Km-value of 27 mM. Vigabatrin is able to inhibit the uptake of taurine in intestinal and renal cell culture models. |
Hazard Symbols | Xi - Irritant![]() |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
WGK Germany | 3 |
RTECS | MP7745000 |
HS Code | 2922498050 |
Toxicity | LD50 oral in rat: 3gm/kg |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 7.742 ml | 38.712 ml | 77.423 ml |
5 mM | 1.548 ml | 7.742 ml | 15.485 ml |
10 mM | 0.774 ml | 3.871 ml | 7.742 ml |
5 mM | 0.155 ml | 0.774 ml | 1.548 ml |